Levantamiento batimétrico en el islote Montaña Clara (Islas Canarias).

Los objetivos del presente Proyecto Fin de Carrera, serán el levantamiento cartográfico en detalle de la zona de trabajo propuesta, mediante la utilización del Buque Oceanográfico Emma Bardán y su sistema de ecosonda multihaz de alta resolución. Los trabajos asociados serán: El reconocimiento batimétrico sistemático del Islote Montaña Clara con recubrimiento al 100% (ecosonda Multihaz EM-3002D). Toma de datos sistemáticos de perfiles de velocidad del sonido en el agua. Los objetivos específicos del presente Proyecto Fin de Carrera son proporcionar documentación cartográfica que contribuya a la investigación del fondo marino de la plataforma continental del Islote Montaña Clara, tanto por métodos indirectos como directos. Las fases de trabajo son: Procesar y tratar los datos obtenidos en la campaña, para la obtención de mapas,cartas e informes. Elaborar una carta batimétrica basada en datos multihaz con cobertura al 100% del área propuesta. Realizar el tratamiento informático necesario para la integración de los datos en un Sistema de Información Geográfica (S.I.G.)

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio